Latanoprost Comp. Al (Latanoprost, Timolol)

• Latanoprost Comp. Al is indicated for conditions affecting intra‑ocular pressure within the glaucoma disease family.
• Open‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage.
• Ocular hypertension: lowers pressure to prevent progression to glaucoma.
• Secondary glaucoma (e.g., pseudoexfoliative): provides additional pressure reduction when monotherapy is insufficient.

• Latanoprost increases uveoscleral outflow by remodeling the extracellular matrix of the ciliary body, while timolol blocks β‑adrenergic receptors in the ciliary epithelium, decreasing aqueous humor production. The combined actions result in a greater net reduction of intra‑ocular pressure than either agent alone.

Adverse reactions may occur with ocular administration of Latanoprost Comp. Al.

Common Side Effects

• Eye irritation or burning sensation.
• Transient blurred vision.
• Conjunctival hyperemia (redness).
• Increased eyelash growth.
• Periorbital skin darkening.
• Mild headache.

Serious or Rare Side Effects

• Persistent ocular inflammation or uveitis.
• Severe allergic reaction (angio‑edema, anaphylaxis).
• Significant reduction in heart rate or bronchospasm in susceptible patients.
• Visual field loss unrelated to pressure control.
• Systemic hypotension.
• Acute angle‑closure glaucoma (rare).

• Patients should be aware of specific safety considerations before using Latanoprost Comp. Al.
• Pregnancy: safety not established; avoid unless clearly needed.
• Breastfeeding: unknown excretion; weigh benefits against potential risks.
• Respiratory disease: use caution in asthma or COPD due to beta‑blockade.
• Cardiovascular disease: monitor heart rate and blood pressure.
• Contact lens wearers: remove lenses before instillation and wait 15 minutes before reinserting.
• Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost Comp. Al may interact with other medications affecting ocular or systemic physiology.

Major Interactions (Avoid)

• Non‑selective beta‑blockers (e.g., propranolol) – additive systemic beta‑blockade.
• Sympathomimetic eye drops – opposing ocular pressure effects.
• MAO inhibitors – potential for exaggerated hypotensive response.

Moderate Interactions (Monitor Closely)

• Systemic antihypertensives – monitor blood pressure.
• Anticholinergic agents – may affect tear production.
• Topical corticosteroids – increased risk of ocular hypertension.
• Other prostaglandin analogs – avoid concurrent use due to additive side effects.